300511 Shanghai Xuerong Bio-Technology
- 3.45
- +0.06+1.77%
Shanghai Xuerong Bio-Technology News
Xuerong Biotech (300511.SZ) reported first-quarter results, net profit of 5.2403 million yuan, a year-on-year decrease of 97.65%
Xuerong Biotech (300511.SZ) released its report for the first quarter of 2024. The company achieved operating income during the reporting period...
Xuerong Biotech (300511.SZ) holds 1.96% shareholder Zhu Huancheng plans to liquidate and reduce holdings
Xuerong Biology (300511.SZ) announced that Zhu Huancheng, a specific shareholder of the company, plans to make three transactions from the date of publication of this announcement...
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Share Price Boosted 25% But Its Business Prospects Need A Lift Too
Those holding Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) shares would be relieved that the share price has rebounded 25% in the last thirty days, but it needs to keep going to repair the re
Xuerong Biology (300511.SZ)'s edible fungus products are generally sold around production bases, radiating surrounding areas
Gelonghui March 19 | Xuerong Biotech (300511.SZ) said on the investor interactive platform that the company currently has eight major domestic production bases: Changchun, Jilin, Dezhou, Guangdong, Dujiangyan, Sichuan, Bijie, Guizhou, Linyi, Gansu, Guigang, Guangxi, and Huai'an, Jiangsu. The company's edible fungus products are generally sold around production bases and surrounding areas.
Xuerong Biotech (300511.SZ): Plans to use capital raising related claims to increase capital for wholly-owned subsidiaries
Gelonghui, Feb. 23, 丨 Xuerong Biotech (300511.SZ) announced that the company increased its capital at RMB 1 yuan/share through debt-for-share swaps of 170 million yuan in part of the debt raised against its wholly-owned subsidiary Guangxi Xuerong Biotechnology Co., Ltd. (“Guangxi Xuerong”). After the capital increase is completed, the registered capital of Guangxi Xuerong will increase from 10 million yuan to 270 million yuan, and it is still a wholly-owned subsidiary of the company.
Revenues Working Against Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Share Price Following 26% Dive
Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) shareholders that were waiting for something to happen have been dealt a blow with a 26% share price drop in the last month. The drop over the
Xuerong Biotech (300511.SZ) and related personnel accepted the Shanghai Securities Regulatory Bureau's administrative supervision measures decision
Xuerong Biotech (300511.SZ) issued an announcement. The company received the Shanghai Securities Regulatory Bureau on December 25, 2023...
Xuerong Biotech (300511.SZ): Net loss of 169 million yuan in the third quarter
On October 27, Gelonghui Biotech (300511.SZ) announced its report for the third quarter of 2023. Operating income for the reporting period was 569 million yuan, a year-on-year decrease of 15.86%; net profit attributable to shareholders of listed companies was -169 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -172 million yuan; and basic earnings per share was -0.34 yuan.
Returns On Capital Are Showing Encouraging Signs At Shanghai Xuerong BiotechnologyLtd (SZSE:300511)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? One common approach is to try and find a company with returns on capital employed
Xuerong Biotech (300511.SZ): The controlling shareholder's concerted action has reduced its holdings by 0.67% at the end of Yinwan Huayi's holdings reduction of No. 1
GLONGHUI, August 14丨Xuerong Biotech (300511.SZ) announced that the company recently received a “Notice Concerning the Expiration of the Stock Holding Reduction Plan” issued by Yinwan Huayi No. 1, co-actor of Mr. Yang Yongping, the controlling shareholder of the company. As of August 13, 2023, the term of Yinwan Huayi No. 1's holdings reduction plan has expired. It reduced its holdings by a total of 3.3654 million shares, a change ratio of 0.67%.
Zhu Huancheng, a shareholder of Xuerong Biotech (300511.SZ), reduced his holdings by a total of 3.257 million shares at the end of the holdings reduction period
According to the Zhitong Finance App, Xuerong Biotech (300511.SZ) announced that the term of the company's shareholder Zhu Huancheng's holdings reduction plan has expired, reducing the company's holdings by a total of 3.257 million shares.
A Look At The Fair Value Of Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Shanghai Xuerong BiotechnologyLtd fair value estimate is CN¥6.64 Current share price of CN¥7.26 suggests Shanghai Xuerong BiotechnologyLtd is
Shanghai Xuerong BiotechnologyLtd (SZSE:300511 Investor Five-year Losses Grow to 40% as the Stock Sheds CN¥352m This Past Week
Ideally, your overall portfolio should beat the market average. But in any portfolio, there will be mixed results between individual stocks. At this point some shareholders may be questioning their
Does Shanghai Xuerong BiotechnologyLtd (SZSE:300511) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Shanghai Xuerong Biotechnology Co.,Ltd.'s (SZSE:300511) Stock Price Dropped 11% Last Week; Individual Investors Would Not Be Happy
A look at the shareholders of Shanghai Xuerong Biotechnology Co.,Ltd. (SZSE:300511) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company
Xuerong creature: shareholder Yang Yongping reduced his shares in the company by 5.9934% at the expiration of the plan.
Xuerong Bio (300511) announced that the company recently received a written notice from Yang Yongping that its current reduction plan had expired as of February 8, 2022. During the period from December 15, 2021 to December 28, 2021, Yang Yongping reduced a total of 26486050 shares of the company, accounting for 5.9934% of the company's total share capital.
Xuerong Biotech: General Manager Chen Xin plans to increase his holdings by no less than 1 million shares and no more than 2 million shares
Xuerong Biotech (300511) announced that Ms. Chen Xin, the director and general manager of the company, plans to increase her holdings of the company within 6 months from the date of disclosure of this announcement. There is no price precondition for this increase. The holdings increase will be implemented at an opportunity based on secondary market conditions. The number of shares increased this time will not be less than 1 million shares, not more than 2 million shares.
The latest announcement of Xuerong Biology: shareholder Zhu Huancheng intends to reduce his stake of no more than 0.98%.
Xuerong biological announcement, shareholder Zhu Huancheng intends to reduce no more than 0.98% of the shares, the reduction period from the date of the announcement within six months after three trading days. The chairman of the company is Yang Yongping. Mr. Yang Yongping: born in April 1969, Chinese nationality, no permanent residence abroad, college degree, has worked in the Waterway Department of Fujian Port and Navigation Administration, and has served as general manager and chairman of Gaorong Food. He is currently the chairman of the company, vice president of China Edible Fungi Association, Vice Chairman of China Agricultural industrialization leading Enterprises Association, Chairman of Factory Professional Committee of China Edible Fungi Association, Honorary President of Shanghai vegetable Edible Fungi Industry Association, Shanghai Federation of Industry and Commerce
News flash: the limit of Xuebong Bio was reported at 9.68 yuan.
China Finance Online Co Ltd reported that Xuelong Bio opened today at 8.03 yuan. As of 14:30, the stock was up 19.95% at 9.68 yuan, blocking the limit. Yesterday (2022-01-11) the net outflow of the stock was-18.4228 million yuan, the main net outflow was-383800 yuan, the net outflow of the single unit was-13.6073 million yuan, and the net outflow of retail investors was-4.4317 million yuan. (to view the real-time capital flow, please click) in the last month, Xuebong biology has been on the list of dragons and tigers for a total of 0 times, indicating that Xuebong biological stock is not active. (more dragons
The latest announcement of Xuerong Biology: it is proposed to set up a subsidiary to cut into the field of functional food and health food.
Xuerong Biological announcement, the company plans to set up a wholly-owned subsidiary Shanghai Xuerong Biopharmaceutical Co., Ltd. in Shanghai with its own capital of 30 million yuan. Xuerong Medicine will focus on the commercialization of edible fungus extracts with the functions of promoting white blood cells and activating immune cells, enhancing immunity, antioxidation, antivirus, etc., with emphasis on β-1Rong 3 glucan, β-nicotinamide mononucleotide (NMN) and other products. First of all, cut into functional food, health food, simultaneous development of edible fungus extract in anti-tumor, enhance immunity and other aspects of new drug research and development. The chairman of the company is Yang Yongping. Mr. Yang Yongping: April 1969
Analysis
Price Target
No Data
